Benitec Biopharma Inc. (BNTC) Research

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

Market snapshot

Symbol
BNTC
Price
$12.15
Day change
+2.97%
Market cap
$318.9M
P/E ratio
-12.27x
52-week range
9.85-16.76
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months
Analyst price target
$25.00

Peer companies

  • Autolus Therapeutics plc (AUTL)
  • Galectin Therapeutics Inc. (GALT)
  • I-Mab (IMAB)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Neurogene Inc. (NGNE)
  • Ocugen, Inc. (OCGN)
  • PureTech Health plc (PRTC)
  • Quantum-Si incorporated (QSI)

Recent insider activity

  • Friedman David Matthew — A-Award (35000 shares) on 2026-05-26
  • Friedman David Matthew — trade (0 shares) on 2026-05-22
  • Mates Sharon — A-Award (31500 shares) on 2026-01-22
  • SUVRETTA CAPITAL MANAGEMENT, LLC — P-Purchase (65800 shares) on 2025-12-29
  • SUVRETTA CAPITAL MANAGEMENT, LLC — P-Purchase (14320 shares) on 2025-12-26

Open Benitec Biopharma Inc. (BNTC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.